Ro

Ro is a direct-to-consumer telehealth platform offering virtual consultations, prescriptions and medication delivery for conditions including erectile dysfunction, hair loss, weight management and skincare. It combines telemedicine with a pharmacy network and manufacturer distribution partnerships for branded GLP-1 drugs. Ro has also offered fertility-testing services.

32/ 100
Early Warning
1No Decay↑Improving

Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-10-23. Score revised 2026-10-23: 40 → 32.

Score History

MilestoneCriticalMajor
ED Telehealth Launch (2017–2020) · 13/100ED Telehealth LaunchPandemic Hypergrowth (2020–2022) · 20/100Pandemic HypergrowthVC Correction Era (2022–2023) · 28/100VCGLP-1 Pivot (2023–2024) · 33/100GLP-1 PivotBranded GLP-1 Channel (2024–present) · 32/100Branded GLP-1 Channel100755025020182020202220242026-10ED Telehealth Launch (2017–2020) · 13/100Pandemic Hypergrowth (2020–2022) · 20/100VC Correction Era (2022–2023) · 28/100GLP-1 Pivot (2023–2024) · 33/100Branded GLP-1 Channel (2024–present) · 32/1001320283332MilestonesRoman launched (2017)Rebranded to Ro (2018)Acquired Modern Fertility (2021)Events

Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.

ED Telehealth Launch
13/100
2017-10-31 – 2020-03-04

Roman launches on October 31, 2017 with $15 online consultations and discreet ED medication delivery. It rebrands as Ro in 2018 and adds smoking cessation, hair loss and the Rory women's-health brand. In January 2020 it agrees to source all its generic sildenafil from Pfizer's Greenstone. Pricing is simple and the startup has few extraction levers.

Pandemic Hypergrowth
20/100+7
2020-03-04 – 2022-06-23

Ro launches free COVID-19 assessments in March 2020 and rides the telehealth boom. It raises a $200M Series C at $1.5B, then a $500M Series D at $5B, then $150M at $7B by February 2022. Ro Pharmacy offers $5-a-month generics, and Ro buys WorkPath, Modern Fertility, Kit and Dadi. Strain shows by late 2021: employees describe low morale and churn, a TCPA class action over marketing texts is sent to arbitration, and the COO leaves in February 2022.

VC Correction Era
28/100+8
2022-06-23 – 2023-01-20

Ro cuts 18% of staff in June 2022, four months after its $7B round, and co-founder Rob Schutz steps back in August. In December 2022 The Markup and STAT find Roman and Rory sending checkout events, URLs and questionnaire answers to tech platforms. Ro responds that it is not a HIPAA covered entity. Cost-cutting and privacy questions define the period.

GLP-1 Pivot
33/100+5
2023-01-20 – 2024-12-11

Ro launches the Body weight-loss program in January 2023. Its membership, later reported at $145/month, is billed separately from GLP-1 medication bought through insurance or at list price. The FTC and HHS send industry-wide warnings about tracking in July 2023, and PioneerRx sues Ro that month alleging trade-secret misuse. The two-charge structure becomes the root of later billing complaints.

Branded GLP-1 Channel
32/100-1
2024-12-11 – present

Ro becomes the first platform integrated with LillyDirect in December 2024 and adds NovoCare in April 2025, moving to manufacturer-direct cash prices for branded GLP-1s. Celebrity campaigns with Charles Barkley and Serena Williams lead up to a February 2026 Super Bowl ad. Through 2026 prices fall: Ro adds the Wegovy pill, the Zepbound KwikPen and Foundayo, prepaid Wegovy plans and a membership as low as $74/month on an annual plan. BBB complaints about billing and cancellation continue.

Alternatives

Mark Cuban’s pharmacy publishes medication cost breakdowns with a 15% markup, pharmacy labor charges, and separate shipping. Many generic listings have a $5 pharmacy labor fee, while some medications have higher fees. A separate prescriber is needed, and savings depend on the drug and other available pharmacy prices.

GoodRx46/100

Prescription discount platform that helps find the lowest medication prices across pharmacies. GoodRx also offers its own telehealth consultations. Useful for price comparison and can significantly reduce out-of-pocket medication costs when combined with a separate telehealth provider.

A publicly traded DTC telehealth competitor offering services for weight loss, hair loss, erectile dysfunction, and skincare. Patients can compare available treatments and total care and medication costs; changing providers may require a new clinical evaluation.

Dimensional Breakdown

Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.

User Value Erosion
Ro's core service works and has expanded. Since late 2025 it has added the Wegovy pill (January 2026), the Zepbound KwikPen and Foundayo (April 2026), and it reported that an in-house LLM triage tool cut mean care-team response time to adverse-event messages from 115.1 to 33 minutes. Remaining frictions come from BBB complaints about prior-authorization handling, prescription delays and billing. A June 2026 KFF Health News report also noted that Ro sometimes prescribes GLP-1s after an asynchronous evaluation with no live conversation; Ro says it holds real-time visits where state law requires them or on request. These are minor annoyances, not a degraded core product.
How It Got Here
When Roman launched on October 31, 2017, the offer was simple: a $15 online consultation, a licensed physician and discreet ED medication delivery. In 2020 Ro added free COVID-19 assessments, which Uber promoted to independent workers, and Ro Pharmacy offered more than 500 generics at $5 a month per drug. The acquisitions of WorkPath, Kit and Dadi added at-home testing. The January 2023 Body Program brought GLP-1 access, labs, provider care and coaching. Its membership, later reported at $145 a month, was billed separately from medication, and some users say they misunderstood that. Branded supply arrived through LillyDirect in December 2024 and NovoCare in April 2025. Since late 2025 the offering has widened and become cheaper. Ro reported an LLM triage tool that cut mean response time to adverse-event messages from 115.1 to 33 minutes, and it published a peer-reviewed 68-week semaglutide study. In early 2026 it added the Wegovy pill, the Zepbound KwikPen and Foundayo, alongside prepaid plans. Frictions remain. BBB complaints describe prescription delays, disputed prior-authorization handling and slow support. A June 2026 KFF Health News report noted that Ro sometimes prescribes GLP-1s after an asynchronous evaluation with no live conversation; Ro says it holds real-time visits where state law requires them or on request. Sacra's roughly 50% annual churn estimate for Ro and Hims dates from October 2022, before Body launched.
Business Customer Exploitation
Shareholder Extraction
Lock-in & Switching Costs
Twiddling & Algorithmic Opacity
Dark Patterns
Advertising & Monetization Pressure
Competitive Conduct
Labor & Governance
Regulatory & Legal Posture

Dimension History

2017ED Telehealth Launch2020Pandemic Hypergrowth2022VC Correction Era2023GLP-1 Pivot2024Branded GLP-1 ChannelUser Value11233Biz Exploit11122Shareholder23333Lock-in12233Algorithms11343Dark Patterns12344Advertising12344Competition13333Labor/Gov23433Regulatory22444
Timeline (44 events)
major2017-10-31

Roman launches as DTC men's health telehealth platform

Zachariah Reitano, Saman Rahmanian, and Rob Schutz launch Roman, a direct-to-consumer telehealth platform focused on erectile dysfunction treatment. The service offers $15 online consultations with licensed physicians and discreet medication delivery, targeting the stigma around men's sexual health. The company raises $3.1 million in seed funding led by General Catalyst.

major2018-09-18

Roman rebrands to Ro, expands beyond ED

Less than a year after launch, Roman's parent platform rebrands to Ro and unveils Zero, a smoking-cessation kit. The rebrand signals broader ambitions beyond men's sexual health. Alexis Ohanian joins the board during an $88 million Series A round led by FirstMark Capital.

minor2019-03-20

Ro launches Rory for women's menopause health

Ro enters the women's health market with Rory, a telehealth service specializing in menopause symptoms including hot flashes, vaginal dryness, and insomnia. Online consultations start at $15 with personalized treatment plans including prescriptions like estradiol cream and melatonin. The expansion marks Ro's shift from a single-condition platform to a multi-vertical telehealth company.

minor2020-01-24

Roman agrees to source all its generic Viagra from Pfizer's Greenstone

Roman and Pfizer subsidiary Greenstone struck a deal for Roman to source all the generic sildenafil citrate it sells directly from Pfizer, which then had the only FDA-approved authorized generic. Fortune described the goal as quality control and supply-chain transparency for customers.

major2020-03-04

Ro launches free COVID-19 telehealth assessments nationwide

Ro launches a free COVID-19 telehealth assessment nationwide in March 2020, reviewing symptoms, travel history and exposure risk. Its later FAQ reports helping patients in every state plus Washington, DC, and more than 70 companies and organizations.

D1D8
Ro ↗
major2020-07-27

Ro raises $200M Series C at $1.5B unicorn valuation

Ro closes a $200 million Series C led by General Catalyst at a $1.5 billion valuation, bringing total funding to $376 million. The company says it is generating $250 million in annual revenue without taking insurance. It plans to expand into at-home diagnostics. TechCrunch reports that the new investment will support Ro's Collaborative Care Center and national pharmacy operating system.

major2020-07-27

Ro Pharmacy offers 500+ generics at $5 a month per drug

Alongside its Series C, TechCrunch reported that Ro had a new online cash-pay pharmacy business, Ro Pharmacy, offering more than 500 generic medications for $5 per month per drug.

minor2020-12-08

Ro acquires WorkPath for in-home care services

Ro makes its first acquisition, purchasing WorkPath, an AI-powered platform that dispatches phlebotomists to patients' homes for blood draws and diagnostic testing. The acquisition enables Ro to offer in-home care services nationwide, expanding beyond purely virtual consultations into a hybrid care model that combines telehealth with physical diagnostic infrastructure.

critical2021-03-23

Ro raises $500M Series D at $5B valuation

Ro closes a $500 million Series D led by General Catalyst, FirstMark Capital and TQ Ventures, with new investors including Altimeter Capital, Baupost Group and Dragoneer. The $5 billion valuation is more than triple its prior $1.5 billion valuation, and total funding reaches $876 million. Ro says it will strengthen telehealth, pharmacy distribution and in-home care, enhance its medical-record system and develop remote patient monitoring.

major2021-05-19

Ro acquires Modern Fertility for $225M+

Ro acquires Modern Fertility, a women's reproductive health company focused on fertility testing and education, in a deal reported to exceed $225 million. Modern Fertility co-founders Afton Vechery and Carly Leahy will lead Ro's women's health vertical. The deal follows Ro's December 2020 Workpath acquisition, continuing its vertical-integration strategy.

minor2021-06-30

Ro acquires at-home diagnostics company Kit

Ro announced the acquisition of Kit, an at-home diagnostics company, saying it expanded the diagnostics capabilities and lab infrastructure of its vertically integrated platform. It followed the WorkPath and Modern Fertility deals.

D8D4
Ro ↗
major2021-10-27

Employees describe low morale and churn at Ro

Ten current and former employees told TechCrunch of a low-morale work environment and churn across teams, which they attributed partly to leadership's strategy and response to feedback. Employees said eight of the 11-person customer service operations team had quit over culture. A Ro spokesperson cited high internal engagement scores and workplace awards.

minor2021-10-27

Court sends TCPA class action against Ro to individual arbitration

Sergio Costa's putative class action alleged that Ro sent unsolicited marketing texts in violation of the Telephone Consumer Protection Act. The Southern District of New York granted Ro's motion to compel arbitration and dismissed the complaint without prejudice, without ruling on the truth of the allegations.

major2022-02-15

Ro raises $150M at $7B valuation from existing investors

Ro raises $150 million exclusively from existing investors led by ShawSpring Partners at a $7 billion valuation, bringing cumulative primary funding to approximately $1 billion. The round follows its $500 million March 2021 financing. TechCrunch notes that the absence of new investors and expansion beyond the core ED business could bring added pressure to deliver on newer verticals.

minor2022-02-24

Ro's COO and Ro Pharmacy GM depart

A week after Ro's $7 billion round, CEO Zachariah Reitano told employees in an email obtained by TechCrunch that COO George Koveos and Ro Pharmacy general manager Steve Buck were moving on in the coming weeks, with Buck remaining an outside advisor to Ro Pharmacy.

minor2022-03-01

Ro acquires Dadi and launches Ro Sperm Kit

Ro announced the acquisition of Dadi, a company specializing in sperm testing, analysis and storage, and launched a rebranded Ro Sperm Kit using Dadi's collection, testing and storage kit. The deal followed its Modern Fertility acquisition.

critical2022-06-23

Ro lays off 18% of workforce months after $150M raise

Ro cuts 18% of its staff, four months after raising $150 million. CEO Zachariah Reitano cites managing expenses, increasing organizational efficiency and aligning resources with strategy. TechCrunch sources say most of the recruiting team is affected and remaining employees hear the news on Zoom without a chance to ask questions; Ro says departing employees were notified in individual conversations.

major2022-08-02

Co-founder Rob Schutz departs amid restructuring

Rob Schutz, Ro's co-founder and chief growth officer, announces he will step back from daily operations after Labor Day, September 5, 2022, and remain involved as an adviser. The announcement comes weeks after the 18% workforce reduction. Schutz says Ro has reached a scale where he can pass responsibility to existing teams.

minor2022-10-06

Analysis describes Ro's monthly prescription subscription model

Sacra describes Ro and Hims as offering free consultations and monetizing through generic Viagra sold on monthly subscriptions.

critical2022-12-13

Markup investigation exposes Ro sharing health data with big tech

The Markup and STAT examine 50 direct-to-consumer telehealth websites and find that 49 send visited URLs and IP addresses to at least one tech company. Trackers on 25 sites, including Ro, send cart or treatment-subscription checkout events. Their underlying dataset distinguishes Roman's URL sharing and TikTok checkout tracking from Rory's Facebook questionnaire/cart tracking and TikTok cart tracking. The investigators cannot independently confirm how or whether the receiving platforms use all the sensitive data. A bipartisan Senate inquiry follows in February 2023.

minor2022-12-19

Lyon Firm announces Ro data-tracking privacy investigation

The Lyon Firm announces that it is investigating Ro telehealth websites for potential data-tracking and health-privacy violations, citing The Markup reporting. The firm alleges that tracking code on telehealth websites can share medical and personal information with technology companies without user consent.

critical2023-01-20

Ro launches Body weight loss program with GLP-1 access

Ro launches the Body Program, offering access to GLP-1 medications, diagnostic testing with at-home sample collection, personalized provider care and one-to-one nurse coaching.

major2023-02-07

Bipartisan senators launch inquiry into telehealth data tracking

Senators Amy Klobuchar, Susan Collins, Maria Cantwell, and Cynthia Lummis send letters to telehealth companies requesting information about their data sharing practices, prompted by The Markup's December 2022 investigation. While the letters target Cerebral, Monument, and Workit Health directly, the inquiry creates regulatory pressure across the entire DTC telehealth industry, including Ro.

minor2023-07-10

PioneerRx sues Ro alleging pharmacy-software trade-secret misuse

Pharmacy software vendor PioneerRx, which had licensed its system to Ro Pharmacy in 2020, filed six causes of action alleging Ro used the license to misappropriate trade secrets for its own in-house pharmacy software. In October 2024 the court denied Ro's motion to dismiss the Louisiana unfair-trade-practices claim; that ruling addressed the pleading, not whether the allegations were true.

major2023-07-20

FTC and HHS warn telehealth providers about tracking technologies

The FTC and HHS Office for Civil Rights warn approximately 130 hospital systems and telehealth providers about privacy and security risks from online tracking technologies. The letters say trackers could disclose sensitive health information to third parties. Contemporary reporting connects the warning to the broader tracking problem highlighted by STAT and The Markup; it does not identify this as a Ro-specific enforcement finding.

minor2023-11-03

Report examines DTC telehealth regulation and a 2021 ED guideline study

An Undark report, republished by Popular Science, examines regulatory gaps around direct-to-consumer telehealth companies, including Ro. It summarizes a 2021 expert assessment that gave Ro and Hims mixed scores for adherence to erectile-dysfunction treatment guidelines: adequate risk-benefit counseling but shortcomings including advice for men with low testosterone. The article describes the industry's reliance on affiliated clinicians and pharmacy arrangements; Ro also owns pharmacy infrastructure.

minor2024-10-22

CEO Reitano promotes benefits of staying private

Ro CEO Zachariah Reitano says he would never rule out taking the company public but thinks the benefits of remaining private are growing. At Axios' October 22 event he declines to specify IPO plans, saying Ro is focused on delivering a high-quality product for patients. Private status entails fewer public financial disclosures, but his remarks do not establish an intent to avoid scrutiny of patient complaints or pricing.

major2024-12-11

Ro partners with Eli Lilly for Zepbound single-dose vials

Ro becomes the first platform to integrate with LillyDirect, Eli Lilly's direct-to-patient pharmacy channel, giving eligible patients access to Zepbound single-dose vials through Ro's app. The deal adds a branded-drug option to Ro's obesity care.

critical2025-02-21

FDA resolves semaglutide injection shortage and sets compounding transition dates

The FDA determines that the semaglutide injection shortage is resolved. Its announced enforcement-discretion periods run to April 22, 2025, for 503A compounders and May 22 for 503B outsourcing facilities making products that are essentially copies of approved drugs. This constrains shortage-based copy compounding, including the market in which Ro operates; it is not a ban on every individualized compounded formulation. Ro had already arranged branded Zepbound access in December 2024.

major2025-04-29

Ro integrates with NovoCare for Wegovy at $499/month

Ro integrates with NovoCare Pharmacy to offer all Wegovy doses at a $499 monthly medication price, with the Body Program membership billed separately. Novo also partners with Hims & Hers and LifeMD; Hims & Hers announces a $599 starting package including care. The distribution arrangement is non-exclusive.

D7D1D5D2
CNBC ↗
minor2025-04-29

Charles Barkley becomes Ro's celebrity GLP-1 ambassador

Ro announces Charles Barkley as a celebrity patient ambassador. Barkley previously lost nearly 50 pounds on GLP-1s, then regained much of it after supply and access problems interrupted treatment. He restarts with Zepbound vials through Ro's LillyDirect collaboration. The first campaign spot premieres during NBA playoff coverage on TNT.

minor2025-05-22

Ro offers $199 first-month Wegovy and $45 first Body membership month

Ro offered new patients Novo Nordisk's $199 first-month cash price for Wegovy through NovoCare Pharmacy, plus a discounted $45 first month of Body membership, for a combined $244 first month.

D7D1
Ro ↗
major2025-08-21

Serena Williams becomes Ro's celebrity GLP-1 ambassador

Ro announces a multiyear Serena Williams GLP-1 marketing partnership on August 21. Williams discloses a 31-pound weight loss. Her husband Alexis Ohanian is a Ro investor and board member, a relationship disclosed in the campaign and criticized in press commentary. The campaign promotes weight-loss medication as healthcare and seeks to reduce stigma.

major2025-09-19

Report details 50+ FDA warning letters over compounded GLP-1 advertising

STAT reports that the FDA has sent more than 50 warning letters to telehealth businesses and other providers over false or misleading compounded-drug marketing. The letters were sent the preceding week and published September 16. Hims & Hers received a September 9 letter; this is industry enforcement context, not proof that Ro received a letter or was cleared by the FDA.

minor2025-11-04

Ro reports LLM triage cut response times to GLP-1 side-effect messages

Ro presented eight abstracts at ObesityWeek 2025. One evaluated its in-house LLM tool for detecting and triaging messages about GLP-1 adverse events: Ro reported 94% detection accuracy and a fall in mean care-team response time from 115.1 to 33 minutes after implementation.

minor2025-12-10

Ro publishes peer-reviewed 68-week semaglutide outcomes study

Ro published a peer-reviewed study in Obesity of semaglutide treatment through its platform, reporting average weight loss of 16.6% over 68 weeks and a safety profile it said was consistent with clinical trials. The lead author is a Ro advisor.

major2026-01-05

Ro launches the Wegovy pill with Novo Nordisk

Ro announced it was working with Novo Nordisk on the nationwide launch of the Wegovy pill, the first oral GLP-1 for weight loss, at what it called the lowest available cash price. Ro said its direct integration with Novo began in April 2025.

major2026-02-08

Ro debuts Super Bowl ad starring Serena Williams

Ro debuts a Super Bowl LX commercial starring Serena Williams as part of its 'Healthier on Ro' campaign. Ro says she lost 34 pounds and lowered her cholesterol. The ad is the centerpiece of a broader national campaign spanning television, paid social media and outdoor advertising.

minor2026-02-09

Ro registers federal lobbyists for telehealth advocacy

Roman Health Ventures Inc. dba Ro registered under the Lobbying Disclosure Act, effective February 9, 2026, listing education and advocacy related to telehealth and the direct-to-patient model of care delivery as its lobbying issues.

major2026-03-31

Ro adds prepaid Wegovy plans

Ro announced 3-, 6- and 12-month prepaid options for cash-paying Wegovy patients, saying they could save up to $1,200 a year on the pen or $600 a year on the pill, and said lower-priced Body membership options would follow in April.

D7D4
Ro ↗
minor2026-04-02

Ro launches the Zepbound KwikPen

Ro launched Eli Lilly's multi-dose Zepbound KwikPen nationwide, with monthly cash prices of $299 for the 2.5 mg dose, $399 for 5 mg, and $449 for higher doses when refills are completed within 45 days of the previous delivery.

D1D5
Ro ↗
minor2026-04-09

Ro adds Lilly's Foundayo oral GLP-1

Ro began offering Eli Lilly's once-daily oral GLP-1 Foundayo (orforglipron), with a cash price starting at $149 a month for the lowest dose plus membership fees.

major2026-04-22

Ro cuts Body membership prices with prepaid plans

Ro announced lower Body membership prices: $39 for the first month, then 3-, 6- or 12-month prepaid plans, with the annual plan saving up to 50% ($900 a year) and costing $74 a month. Ro said the membership itself was unchanged.

D7D1D4
Ro ↗
minor2026-06-01

KFF Health News notes Ro's asynchronous GLP-1 prescribing

A KFF Health News report on GLP-1 telehealth safety said Ro sometimes requires only an asynchronous evaluation, an intake form and medical questionnaire with no live conversation, before prescribing. A Ro spokesperson said it requires a real-time conversation when state law requires one or when a patient or clinician asks.

Evidence (63 citations)
Scoring Log (6 entries)
fact-audit2026-10-23FABRICATION FOUND

Checked 69 original items: 66 timeline/evidence/milestone items plus3 alternatives, plus all summaries, narratives, eras and metadata. 13 verified,23 corrected (6 date-only),30 re-sourced,3 removed. Strict invented detail: Hims & Hers supposedly absent from September2025 FDA warning recipients; the FDA September9 letter explicitly names Hims (https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hims-09092025). Pricing-scope corrections, dynamic BBB grade/Glassdoor counts, wrong chronology and miscited true facts are not labeled invented. 22 distinct unsupported details or causal claims narrowed or removed after source/origin/date-drift checks; ledger: work/lead-decisions.json. 35 distinct prose claims corrected across10 summaries,10 narratives and4 eras. No scores changed. Added evidence preserves existing facts split onto their supporting sources, including recovered328% growth, historical drug prices, privacy categories and ad details.

regrade2026-10-23RESCORED

40→32. Since Feb 2026: Super Bowl LX ad (Feb), federal lobbying registration (Feb), prepaid Wegovy plans saving up to $1,200/yr (Mar 31), Zepbound KwikPen and Foundayo added (Apr), Body membership cut to $74/mo on annual plan after $39 first month (Apr 22), KFF report on asynchronous GLP-1 prescribing (Jun), Oct 2026 privacy policy permitting customer emails to ad networks; no enforcement, layoffs or funding found. Dimensions: D1 4→3 (event: 2025-26 price cuts, formulary expansion, LLM triage response-time gains; complaints remain minor), D7 5→4 (event: 2026 membership and Wegovy price cuts; layered fee and ad-network data sharing keep it at 4), D10 5→4 (correction: fact audit established Senate/FTC/FDA actions were industry-wide, not Ro findings; legalistic HIPAA stance, arbitration use and ad-network sharing support 4), D2 3→2 (recalibration: no marketplace or fee extraction; PioneerRx allegations unproven), D3 4→3 (recalibration: no buybacks/dividends, single 2022 layoff not during profits), D5 4→3 (recalibration: pricing layered but explicitly published), D6 5→4 (recalibration: complaint allegations, no regulatory finding, account/email cancellation), D9 4→3 (recalibration: labor tension confined to 2021-22). D4 3, D8 3 unchanged. Eras: all 5 re-dated to inflection events: 2017-10-01→2017-10-31 (Roman launch), 2020-01-01→2020-03-04 (free COVID assessments), 2022-06-01→2022-06-23 (18% layoff), 2023-01-01→2023-01-20 (Body launch), 2026-02-19 (assessment date)→2024-12-11 (LillyDirect integration) and relabeled 'Celebrity Marketing Era'→'Branded GLP-1 Channel'. Era scores 13/20/28/33/32. Historical gaps filled: Pfizer Greenstone deal, Ro Pharmacy $5 generics, Kit and Dadi acquisitions, 2021 employee-morale reporting, 2021 TCPA arbitration ruling, Feb 2022 exec departures, PioneerRx suit, May 2025 Wegovy promo. Skipped: Wilson v. Roman (Oct 2025 settlement-in-principle dismissal; claim type not confirmable from order), Fifth Circuit FDA shortage ruling (not Ro-specific), Amgen/Novo research announcements and RAID-FN scale (no scoring effect), Paytas campaign (date ambiguous on archive page). Alternatives reviewed, unchanged. Category Telehealth fine.

restore-check2026-10-23RESTORED

Checked all 16 candidates: 1 restored, 4 partly restored, 6 confirmed removed, 5 already present (the supported portions; unsupported embellishments remain excluded). timeline:remove:16 — PARTLY RESTORED: The Lyon Firm announcement is readable via Wayback (snapshot 20260121025039). It was published December 19, 2022, not June 1, 2023. Restore the firm announcing an investigation and its attributed allegations; do not turn its industry-wide questionnaire/recipient discussion into a Ro-specific finding. timeline:remove:9 — PARTLY RESTORED: Original Vator URL and variants return 404; Wayback retries failed. Three searches found the original headline and contemporaneous Vator coverage, but no readable original. A readable Sacra analysis dated October 6, 2022 explicitly describes Ro and Hims monetizing generic Viagra on monthly subscriptions. Restore that narrower subscription-model analysis at its actual date and source. Do not restore consultation fees as Ro revenue, a subscription-innovation attribution to Vator, or causal billing/cancellation claims. timeline:update:3 — ALREADY PRESENT: Uber partnership/promotion is already in evidence[37] and the D1 narrative; Uber April 29 announcement and Ro FAQ read this session confirm it. The original Fast Company URL is blocked and archive failed. Three searches including 2020-2022 drift found no evidence quantifying a significant user-base boost caused by Uber. Supported partnership needs no duplicate restoration; causal growth wording stays out. timeline:update:4 — PARTLY RESTORED: TechCrunch July 27, 2020 explicitly says new investment will support the Collaborative Care Center and national pharmacy operating system. Restore these stated uses of capital while retaining CNBC-supported financing/revenue/at-home diagnostics facts. Do not restore the evaluative claim that revenue validates the business model or assign later in-home care investment to this round. timeline:update:6 — CONFIRMED REMOVED: Undark live/Wayback could not be read, but the Popular Science republication was read. It supports the already-preserved 2021 study and regulatory discussion, not a January 2021 publication or a blanket Ro-specific waiver-to-scaling claim. Three origin/date-drift searches and the readable Ro licensure FAQ did not substantiate the removed causal claim. Ro FAQ says clinicians are licensed in the patient state and laws vary by state; no generic outside-pharmacy-only characterization is restored. timeline:update:7 — ALREADY PRESENT: Regrade D3 summary/narrative already preserves employee-described pressure to grow into the $5B valuation. Read TechCrunch October 27, 2021 and the cited Fierce March 23 funding article. Three searches and Sacra October 2022 analysis do not establish that this financing caused an increase in aggressive marketing spend. Existing pressure finding remains; no causal marketing assertion restored. timeline:update:11 — ALREADY PRESENT: Approximately 750 workers already appears in evidence[8], confirmed by readable Fierce June 24, 2022 reporting. Read cited TechCrunch June 23 report: remaining employees heard on Zoom, departing staff notified individually. Three searches including 2021-2023 drift did not substantiate previous-day reassurance, clinical/customer-service layoffs or resulting degraded patient care. Supported workforce figure needs no duplicate; unsupported harm stays out. timeline:update:12 — CONFIRMED REMOVED: Read cited TechCrunch August 2, 2022: transition after Labor Day rather than effective September 5. Three searches including 2021/2023 drift did not substantiate competitive-position changes or deeper patient lock-in resulting from departure. Retain current corrected leadership account. timeline:update:13 — CONFIRMED REMOVED: Read The Markup December 13, 2022 investigation. It distinguishes questionnaire, cart/checkout, identifying information and URL tracking, and explicitly cannot independently confirm receiving platforms use of collected data. The retained account preserves the supported Ro and industry findings; the blanket claim and asserted actual targeted-ad use are not restored. timeline:update:18 — ALREADY PRESENT: CEO quotation/IPO comments and the attributed Sacra $598M/66% annualized-revenue estimate already remain in the current record. Read the October 22 TechCrunch article. Three searches including the Axios event did not substantiate an accountability-avoidance motive or intent to shield pricing/complaints from scrutiny. No duplicate or unsupported motive is restored. timeline:update:25 — ALREADY PRESENT: First-ever status/blood sugar is already in evidence[39]; post-broadcast backlash is in evidence[40] and narrative. Read Fierce Pharma January 28, Ro production account January 29 and University of Florida Brand Bowl analysis. Two searches did not establish a high-margin Ro weight-loss program or resulting patient-value erosion. Preserve existing supported details without duplicating them. evidence:remove:34 — RESTORED: The actual Lyon Firm publication recovered through Wayback establishes the removed investigation source. Add evidence with its December 19, 2022 publication date and archival URL; not the unsupported June 1, 2023 date. evidence:update:11 — CONFIRMED REMOVED: JustCancel original URL returns 404; archive retries failed. Three exact-title/domain/date-drift searches did not recover readable qualifying coverage. The current Ro terms evidence is retained; do not restore an unverified article/date or imply measured cancellation friction. evidence:update:18 — CONFIRMED REMOVED: The removed detail is a December 1, 2025 publication date on a changing Trustpilot profile. Live and Wayback were unreadable; three date/origin searches did not recover a dated original. Current profile observation and billing/cancellation allegations remain. Failed fetching is not treated as proof that the reviews do not exist. evidence:update:20 — PARTLY RESTORED: Forbes Health Modern Fertility review, published October 9, 2025 and readable in December 10, 2025 Wayback snapshot, explicitly reports Ro BBB accreditation and B rating. Restore as historical, with October 2025 attribution; retain the current A+ observation read from BBB and do not restore the unsupported December 1 date. Three searches total. milestones:update:0 — CONFIRMED REMOVED: Read TechCrunch October 31, 2017 launch reporting, which explicitly says Roman launches today. Two exact/broader founding-date searches did not substantiate October 1 incorporation/founding. Keep the documented launch milestone. Restored additions: Lyon Firm announcement and evidence — The Lyon Firm, December 19, 2022, Wayback January 21, 2026; subscription-model analysis — Sacra, October 6, 2022; historical BBB B-rating evidence — Forbes Health, October 9, 2025, Wayback December 10, 2025. CNBC financing evidence added to preserve the existing revenue/funding attribution while the timeline links to TechCrunch for the restored investment-use detail. No score or history changes.

Deep Enrichment2026-03-12
Alternatives Review2026-02-21GOOD
Initial Scoring2026-02-19